Hyfe

Promising results and progress in chronic cough treatment Sensory Cloud, Inc. and Hyfe announced promising results from a study showing that Sensory Cloud’s inhaled alkaline HDS aerosol significantly reduced cough frequency in patients with refractory chronic cough (RCC), with no significant adverse events. Cough counts were measured continuously using Hyfe’s AI-powered technology. Read more ⬇️ https://lnkd.in/gmGV3fP5

To support the development of an accurate, point-of-care cough-based triage tool for TB, we have compiled a large multi-country database of cough sounds from individuals being evaluated for TB. The dataset includes more than 700,000 cough sounds from 2,143 individuals with detailed demographic, clinical and microbiologic diagnostic information. We aim to empower researchers in the development of cough sound analysis models to improve TB diagnosis, where innovative approaches are critically needed to end this long-standing pandemic. 🔗 Link in the comments

AI-based analysis of cough sounds has the potential to transform the diagnosis and management of tuberculosis in low-resource settings. I'm so proud of Hyfe for our involvement in creating this open and free dataset of 700,000 cough sounds from 2,143 individuals across seven countries, to enable more research in this area cc Simon Grandjean Lapierre https://lnkd.in/dVG2JsxR

🌍 New Publication Using an earlier version of Hyfe's cough monitoring technology, this research demonstrates the feasibility of community-based cough monitoring in low-resource settings. As we look back, it's remarkable to see how far and fast we've come. Technical innovation now makes this level of health monitoring at scale a reality, paving the way for scalable solutions in Global Health. Find the link to the publication in the comments #globalhealth #tbcare #cough #coughmonitoring

➡️ 7-day continuous cough monitoring outperforms 24-hour methods ⬅️ This latest Hyfe white paper presents data-driven evidence showing how prolonged monitoring provides more reliable insights for clinical trials and research studies, offering a new standard for understanding cough variability. 🔗 Find the link in the comments

Over 10% of the general population lives with chronic cough. Today, October 15, marks the first-ever #WorldChronicCoughDay, dedicated to raising awareness of the condition and the many challenges faced by those living with it. Discover how Hyfe's cough monitoring technology can make a difference ⬇️

☀️ Life at Hyfe ☀️ How sunny, lovely and productive remote, flexible work can be! Our ML engineer George Kafentzis shares his experience working at Hyfe: "Besides the usual flexibility that remote work allows for families (work while waiting for kids to finish their outdoor activities etc), I am allowed to offer my family a full month of vacations to my hometown, and sometimes join them at the beach in the morning on a working day, thus pushing my working hours for an hour or two later!" #flexibleworking #flexibility #remotework #hyfeai

Hyfe has successfully deployed its AI-powered cough detection technology in a study led by Dr. Carlos J. Chaccour D. at the Universidad de Navarra  🌍 The study, published in Lung Journal, shows how our app objectively tracks and quantifies chronic cough, providing continuous, real-time data. Key insights from the study: 🔬 Significant variability in daily cough rates 📊 Unprecedented data for managing chronic cough and potentially improving treatment strategies With this technology, Hyfe is advancing respiratory health monitoring into the era of precision medicine. Our mission: to make cough monitoring as easy and essential as tracking heart rate or blood pressure. We’re excited to expand this research further and collaborate with healthcare providers worldwide!

Hyfe at #CHEST2024 Our CMO, Dr. Peter Small will be attending CHEST 2024 in Boston on October 8th and 9th (Tuesday and Wednesday) We’re excited to connect with innovative clinicians to discuss how continuous, unobtrusive, and privacy-preserving cough monitoring can improve disease diagnosis and patient care! #hyfeai #coughmonitoring

Hyfe cough monitoring technology is used for collecting data within a cardiovascular repository by McGill University Health Center. They use a blood test to measure NT-proBNP and thereby diagnose CHF exacerbations; when a patient enters the hospital with an exacerbation, they monitor the patient's cough with a phone at the patient's bedside to test whether cough decreases over the course of treatment.  The basic design is thus: measure NT-proBNP at the start of treatment (high NT-proBNP = exacerbation), monitor cough throughout, then measure NT-proBNP again at the end (low NT-proBNP = exacerbation has ended). Stay tuned for new insights! #coughresearch #heartfailure #research